Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Study protocol

Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial

Authors: Pia von Blanckenburg, Franziska Schuricht, Ute-Susann Albert, Winfried Rief, Yvonne Nestoriuc

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Adjuvant endocrine therapy can improve disease-free survival and time before recurrence in breast cancer patients. However, it is associated with considerable side effects that negatively affect patients’ quality of life and cause non-adherence. The recently demonstrated effect of individual expectations on side-effect development (nocebo effect) suggests that psychological factors play a role in the prevention of side effects. The aim of this study is to evaluate cognitive-behavioral side-effect prevention training (SEPT) for breast cancer patients. This article describes the study protocol and applied research methods.

Methods/Design

In a randomized controlled trial, 184 female breast cancer patients are assigned to receive either SEPT, standard medical care or a manualized supportive therapy at the start of adjuvant endocrine treatment. SEPT consists of three sessions of cognitive-behavioral training including psychoeducation to provide a realistic view of endocrine therapy, imagination-training to integrate positive aspects of medication into daily life, and side-effect management to enhance expectations about coping ability. Side effects three months after the start of endocrine therapy serve as primary outcomes. Secondary outcomes include quality of life, coping ability and patients’ medication adherence. Patients’ expectations (i.e., expectations about side effects, coping ability, treatment and illness) are analyzed as mediators.

Discussion

The optimization of expectations might be a potential pathway in health care to improve patients’ quality of life during long-term medication intake. The results will provide implications for a possible integration of evidence-based prevention training into clinical practice.

Trial registration

ClinicalTrials.gov, (NCT01741883).
Appendix
Available only for authorised users
Literature
1.
Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, et al: American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010, 28: 3784-3796. 10.1200/JCO.2009.26.3756.CrossRefPubMed
2.
Kreienberg R, Albert US, Follmann M, Kopp I, Kühn T, Wöckel A, Zemmler T: Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Leitlinienprogramm Onkologie. Edited by: AWMF, Deutsche Krebsgesellschaft e.V. und Deutsche Krebshilfe e.V. 2012, Zuckschwerdt: München
3.
Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, et al: Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010, 28: 509-518. 10.1200/JCO.2009.23.1274.CrossRefPubMed
4.
Howell A, Cuzick J, Baum A, Buzdar A, Dowsett M, Forbes J, Hoctin-Boes G, Houghton J, Locker GY, Tobias S: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005, 365: 60-62.CrossRefPubMed
5.
Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P: Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol. 2009, 20: 431-436.CrossRefPubMed
6.
Neugut A, Hillyer G, Kushi L, Lamerato L, Leoce N, Nathanson S, Ambrosone C, Bovbjerg D, Mandelblatt J, Magai C, et al: Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat. 2012, 134: 419-428. 10.1007/s10549-012-2066-9.CrossRefPubMedPubMedCentral
7.
Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai W-Y, Fehrenbacher L, Lin Gomez S, Miles S, Neugut AI: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010, 28: 4120-4128. 10.1200/JCO.2009.25.9655.CrossRefPubMedPubMedCentral
8.
Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A: Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008, 26: 556-562. 10.1200/JCO.2007.11.5451.CrossRefPubMed
9.
Hershman D, Shao T, Kushi L, Buono D, Tsai W, Fehrenbacher L, Kwan M, Gomez S, Neugut A: Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011, 126: 529-537. 10.1007/s10549-010-1132-4.CrossRefPubMed
10.
Demissie S, Silliman RA, Lash TL: Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol. 2001, 19: 322-328.PubMed
11.
Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A: Quality of life of postmenopausal women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006, 100: 273-284. 10.1007/s10549-006-9260-6.CrossRefPubMed
12.
Cella D, Fallowfield L: Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2008, 107: 167-180. 10.1007/s10549-007-9548-1.CrossRefPubMed
13.
Gibson L, Lawrence D, Dawson C, Bliss J: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2009, 4: CD003370
14.
Barsky AJ, Saintfort R, Rogers MP, Borus JF: Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002, 287: 622-627. 10.1001/jama.287.5.622.CrossRefPubMed
15.
Rief W, Avorn J, Barsky AJ: Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Arch Intern Med. 2006, 166: 155-160. 10.1001/archinte.166.2.155.CrossRefPubMed
16.
Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, et al: Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005, 23: 6931-6940. 10.1200/JCO.2005.11.181.CrossRefPubMed
17.
Colloca L, Miller FG: Role of expectations in health. Curr Opin Psychiatr. 2011, 24: 149-10.1097/YCO.0b013e328343803b.CrossRef
18.
Rief W, Bingel U, Schedlowski M, Enck P: Mechanisms involved in placebo and nocebo responses and implications for drug trials. Clin Pharmacol Ther. 2011, 90: 722-726. 10.1038/clpt.2011.204.CrossRefPubMed
19.
Nestoriuc Y, Orav EJ, Liang MH, Horne R, Barsky AJ: Predection of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines. Arthritis Care Res. 2010, 62: 791-799.CrossRef
20.
Roscoe JA, Jean-Pierre P, Shelke AR, Kaufman ME, Bole C, Morrow GR: The role of patients’ response expectancies in side effect development and control. Curr Probl Cancer. 2006, 30: 40-98. 10.1016/j.currproblcancer.2005.12.001.CrossRefPubMed
21.
Colagiuri B, Zachariae R: Patient expectancy and post-chemotherapy nausea: a meta-analysis. Ann Behav Med. 2010, 40: 3-14. 10.1007/s12160-010-9186-4.CrossRefPubMed
22.
Sohl SJ, Schnur JB, Montgomery GH: A meta-analysis of the relationship between response expectancies and cancer treatment-related side effects. J Pain Symptom Manage. 2009, 38: 775-784. 10.1016/j.jpainsymman.2009.01.008.CrossRefPubMedPubMedCentral
23.
Nestoriuc Y, Schuricht F, von Blanckenburg P, Albert US, Rief W: Der Einfluss von Erwartungen auf den Behandlungsverlauf der Antihormonellen Therapie bei Brustkrebs-Patientinnen [abstract]. Verhaltenstherapie. 2011, 21 (Suppl 1): 17-
24.
Nestoriuc Y, Schuricht F, von Blanckenburg P, Rief W, Albert US: Communicating side effects by informing about possible benefits and harms: effects on breast cancer patients’ satisfaction, knowledge and expectations [abstract]. J Cancer Res Clin Oncol. 2012, 138 (Suppl 1): 77-
25.
Rozema H, Völlink T, Lechner L: The role of illness representations in coping and health of patients treated for breast cancer. Psycho-Oncol. 2009, 18: 849-857. 10.1002/pon.1488.CrossRef
26.
Leventhal H, Nerenz D, Steele DJ: Illness representations and coping with health threats. Handbook of psychology and health volume IV social psychology aspects of health. Edited by: Baum A, Taylor SE, Singer JE. 1984, Hillsdale, New Jersey: Erlbaum, 219-252.
27.
McGinty HL, Goldenberg JL, Jacobsen PB: Relationship of threat appraisal with coping appraisal to fear of cancer recurrence in breast cancer survivors. Psycho-Oncol. 2012, 21: 203-210. 10.1002/pon.1883.CrossRef
28.
Benedetti F, Lanotte M, Lopiano L, Colloca L: When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience. 2007, 147: 260-271. 10.1016/j.neuroscience.2007.02.020.CrossRefPubMed
29.
Liu L, Fiorentino L, Natarajan L, Parker BA, Mills PJ, Sadler GR, Dimsdale JE, Rissling M, He F, Ancoli-Israel S: Pre-treatment symptom cluster in breast cancer patients is associated with worse sleep, fatigue and depression during chemotherapy. Psycho-Oncol. 2009, 18: 187-194. 10.1002/pon.1412.CrossRef
30.
de la Cruz M, Hui D, Parsons HA, Bruera E: Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer. 2010, 116: 766-774. 10.1002/cncr.24751.CrossRefPubMedPubMedCentral
31.
Fischer MJ, Wiesenhaan ME, Heijer AD-d, Kleijn WC, Nortier JWR, Kaptein AA: From despair to hope: a longitudinal study of illness perceptions and coping in a psycho-educational group intervention for women with breast cancer. Br J Health Psychol. 2012, DOI:10.1111/j.2044-8287.2012.02100.x
32.
Roscoe JA, O’Neill M, Jean-Pierre P, Heckler CE, Kaptchuk TJ, Bushunow P, Shayne M, Huston A, Qazi R, Smith B: An exploratory study on the effects of an expectancy manipulation on chemotherapy-related nausea. J Pain Symptom Manage. 2010, 40: 379-390. 10.1016/j.jpainsymman.2009.12.024.CrossRefPubMedPubMedCentral
33.
34.
Duijts SFA, van Beurden M, Oldenburg HSA, Hunter MS, Kieffer JM, Stuiver MM, Gerritsma MA, Menke-Pluymers MBE, Plaisier PW, Rijna H, et al: Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol. 2012, 30: 4124-4133. 10.1200/JCO.2012.41.8525.CrossRefPubMed
35.
Mann E, Smith MJ, Hellier J, Balabanovic JA, Hamed H, Grunfeld EA, Hunter MS: Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012, 13: 309-318. 10.1016/S1470-2045(11)70364-3.CrossRefPubMedPubMedCentral
36.
Margraf J: Diagnostisches Kurz-Interview bei psychischen Störungen (Mini-DIPS). 1994, Göttingen: HogrefeCrossRef
37.
Faul F, Erdfelder E, Lang A-G, Buchner A: G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007, 39: 175-191. 10.3758/BF03193146.CrossRefPubMed
38.
Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983, 67: 361-370. 10.1111/j.1600-0447.1983.tb09716.x.CrossRefPubMed
39.
Herrmann C, Buss U, Snaith RR: Hospital anxiety and depression scale - Deutsche Version (HADS-D): manual. 1995, Bern: Huber
40.
Abramson J: WINPEPI updated: computer programs for epidemiologists, and their teaching potential. Epidemiol Perspect Innov. 2011, 8: 1-10.1186/1742-5573-8-1.CrossRefPubMedPubMedCentral
41.
McGurk R, Fallowfield L, Winters Z: Information provision for patients by breast cancer teams about the side-effects of hormone treatments. Eur J Cancer. 2006, 42: 1760-1767. 10.1016/j.ejca.2006.03.014.CrossRefPubMed
42.
Monnier A: Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer. Ann Oncol. 2007, 18: 36-44.CrossRef
43.
Hautzinger M: Die Plazebokontrollgruppe in der Psychotherapieforschung. Psychotherapie. 2001, 6: 199-204.
44.
Markowitz JC, Manber R, Rosen P: Therapists’ responses to training in brief supportive psychotherapy. Am J Psychother. 2008, 62: 67-81.PubMed
45.
Cohen L, Parker PA, Vence L, Savary C, Kentor D, Pettaway C, Babaian R, Pisters L, Miles B, Wei Q, et al: Presurgical stress management improves postoperative immune function in men with prostate cancer undergoing radical prostatectomy. Psychosom Med. 2011, 73: 218-225. 10.1097/PSY.0b013e31820a1c26.CrossRefPubMed
46.
Rief W, Barsky AJ, Glombiewski JA, Nestoriuc Y, Glaesmer H, Braehler E: Assessing general side effects in clinical trials: reference data from the general population. Pharmacoepidemiol Drug Saf. 2011, 20: 405-415. 10.1002/pds.2067.CrossRefPubMed
47.
Rief W, Glombiewski JA, Barsky AJ: General assessment of side effects: GASE. 2009, Bern: Huber (electronic version)
48.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC: The European organization for research and treatment of cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Canc Inst. 1993, 85: 365-376. 10.1093/jnci/85.5.365.CrossRef
49.
Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, et al: The European organization for research and treatment of cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996, 14: 2756-2768.PubMed
50.
Horne R, Weinman J, Hankins M: The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999, 14: 1-10.1080/08870449908407311.CrossRef
51.
Mahler C, Hermann K, Horne R, Ludt S, Haefeli WE, Szecsenyi J, Jank S: Assessing reported adherence to pharmacological treatment recommendations. translation and evaluation of the medication adherence report scale (MARS) in Germany. J Eval Clin Pract. 2010, 16: 574-579.PubMed
52.
Grunfeld EA, Hunter MS, Sikka P, Mittal S: Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005, 59: 97-102. 10.1016/j.pec.2004.10.005.CrossRefPubMed
53.
Broadbent E, Petrie KJ, Main J, Weinman J: The brief illness perception questionnaire. J Psychosom Res. 2006, 60: 631-637. 10.1016/j.jpsychores.2005.10.020.CrossRefPubMed
54.
Grunfeld EA, Low E, Cooper AF: Cancer survivors’ and employers’ perceptions of working following cancer treatment. Occup Med. 2010, 60: 611-617. 10.1093/occmed/kqq143.CrossRef
55.
Mehnert A, Herschbach P, Berg P, Henrich G, Koch U: Progredienzangst bei Brustkrebspatientinnen–Validierung der Kurzform des Progredienzangstfragebogens PA-F-KF. Z Psychosom Med Psychother. 2006, 52: 274-288.PubMed
56.
Mehnert A, Berg P, Henrich G, Herschbach P: Fear of cancer progression and cancer-related intrusive cognitions in breast cancer survivors. Psycho-Oncol. 2009, 18: 1273-1280. 10.1002/pon.1481.CrossRef
57.
Alexander S, Palmer C, Stone P: Evaluation of screening instruments for depression and anxiety in breast cancer survivors. Breast Cancer Res Treat. 2010, 122: 573-578. 10.1007/s10549-009-0669-6.CrossRefPubMed
58.
Albert US, Zemlin C, Hadji P, Ziller V, Kuhler B, Frank-Hahn B, Wagner U, Kalder M: The impact of breast care nurses on patients’ satisfaction, understanding of the disease, and adherence to adjuvant endocrine therapy. Breast Care. 2011, 6 (3): 221-226. 10.1159/000329006.CrossRefPubMedPubMedCentral
59.
Barsky AJ, Goodson JD, Lane RS, Cleary PD: The amplification of somatic symptoms. Psychosom Med. 1988, 50: 510-519.CrossRefPubMed
60.
Gurevich M, Devins GM, Wilson C, McCready D, Marmar CR, Rodin GM: Stress response syndromes in women undergoing mammography: a comparison of women with and without a history of breast cancer. Psychosom Med. 2004, 66: 104-112. 10.1097/01.PSY.0000109907.78754.5A.CrossRefPubMed
61.
Kliem S, Job A-K, Kröger C, Bodenmann G, Stöbel-Richter Y, Hahlweg K, Brähler E: Entwicklung und Normierung einer Kurzform des Partnerschaftsfragebogens (PFB-K) an einer repräsentativen deutschen Stichprobe. Z Klin Psychol Psychother. 2012, 41: 81-89. 10.1026/1616-3443/a000135.CrossRef
62.
Terman LM, Butterwieser P, Ferguson LW, Johnson WB, Wilson DP: Psychological factors in marital happiness. 1983, New York: McGraw-Hill
Metadata
Title
Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial
Authors
Pia von Blanckenburg
Franziska Schuricht
Ute-Susann Albert
Winfried Rief
Yvonne Nestoriuc
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-426

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Nuclear-encoded mitochondrial MTO1 and MRPL41 are regulated in an opposite epigenetic mode based on estrogen receptor status in breast cancer

Research article

The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer

Research article

Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9156 patients

Research article

Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer

Research article

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants

Research article

A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits